

25 Feb 2021 | Analysis

## QUOTED. 25 February 2021. Adam Saltman.

by

A recent FDA action plan on artificial intelligence and machine learning (AI/ML) medical software could encourage more to jump in, said Eko Chief Medical Officer Adam Saltman.

“There are definitely companies, both investors and manufacturers, that have been sitting on the sidelines up until now. Some have read and responded to the original, draft AI/ML document from 2019; others have been silent but watching the landscape. Now they will certainly feel more secure moving forward because they understand the landscape better and also know how to engage with the FDA and their colleagues.” – Adam Saltman, Chief Medical Officer, EKO

- Find out more: [Experts: COVID-19, Departure Of Key FDA Staff Likely Contributing Factors For Delayed AI/ML Action Plan](#)

[Click here](#) for a free trial of *Medtech Insight*